We Challenge You! Join the Melanoma Research Alliance and the Your Cancer Game Plan Challenge!
We’re excited to announce that we’ve joined Merck on the Your Cancer Game Plan Challenge, a social sharing program that will help us raise funds and continue our support of melanoma patients, caregivers, healthcare providers and others.
MRA Raises Millions of Dollars for Groundbreaking Melanoma Research
Normally, when people are at a Sotheby’s auction, they come to bid on beautiful and rare art. On Nov. 2nd, however, more than 240 people came together at Sotheby’s Headquarters in New York City to raise their paddle in the fight against melanoma. Together, participants raised over $20 million to further advance melanoma research.
Safe and Sound: Balancing Safety with Innovation in American Sunscreens
Currently, Americans have access to 16 sunscreen active ingredients approved by the Food and Drug Administration (FDA) to prevent skin cancer. The last time a new OTC (Over the Counter) sunscreen ingredient was added to the FDA sunscreen monograph was 1999. Meanwhile, Europeans have access to 29 sunscreen active ingredients. In the United States there are currently eight new sunscreen ingredients that are pending FDA review, which have been used in Europe – many for over ten years. These new, and potentially better, active ingredients could allow sunscreens to last longer and provide better full spectrum coverage that could help us reverse trends of increasing melanoma incidence in this country. Unlike in Europe where sunscreens are classified as cosmetics, in the United States the FDA is required to evaluate all active ingredients in sunscreens as OTC drugs. Meaning, that all U.S. sunscreen ingredients must be found generally recognized as safe and effective (GRASE) in the same manner as other OTC medications. The FDA says that this is critical to keeping us safe, but is it possible to balance innovation and safety?
Melanoma Research Alliance and the American Cancer Society Forge Research Partnership to Maximize Immunotherapy Benefit to Patients
The Melanoma Research Alliance (MRA) and the American Cancer Society (ACS) are partnering to fund much-needed research aimed at decreasing rare, but serious, side effects associated with checkpoint inhibitors in hopes of increasing further cancer immunotherapy benefit to patients.
MAC: A Valued Partner in the Fight Against Melanoma
What do you do after the melanoma diagnosis has settled in and you’ve done all you can to ensure the best health outcome for yourself? Or even worse, what do you do after you’ve lost a spouse or a child to melanoma? For the members of the Melanoma Action Coalition, the answer is clear. You take that fear or sorrow, and you mobilize.
Melanoma Research Alliance Welcomes New Chief Development Officer
Following 22 years of fundraising and management experience in healthcare, higher education and NPOs, Joan Russo is joining the Melanoma Research Alliance (MRA) as Chief Development Officer.
LFFM Fundraising Event Again Reaches a Record Setting Year
Nearly 1,000 professionals from the leveraged finance community gathered for the sixth annual Leveraged Finance Fights Melanoma (LFFM) benefit and cocktail party raising a record $1.8 million in funds for the Melanoma Research Alliance (MRA), the largest private funder of melanoma research.
MRA and BJ’s Wholesale Club Partner to Launch May Campaign
In today’s dynamic research environment, working as a team is more valuable than ever. This May, in an effort to spotlight Melanoma Awareness month, BJ’s Wholesale Club, a warehouse club operating in 15 states and headquartered in Massachusetts, will launch its first awareness campaign in partnership with MRA to highlight the importance of prevention.
Finance Industry Rallies to Fight Melanoma
Spotlighted in publications like Forbes, Bloomberg and The New York Times, the Leveraged Finance Fights Melanoma (LFFM) event, sponsored annually in New York City by the Melanoma Research Alliance (MRA) has become the premier gathering of professionals from the leveraged finance, private equity, and investment communities – all gathered together in response to melanoma.
Spotlight on MRA’s Ninth Annual Scientific Retreat
By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 28 February 2017 In Allies & Partnerships, Events, Science
In mid-February, MRA held its premiere research event — the 9th Annual Scientific Retreat, in Washington, DC. A total of 297 individuals registered for the meeting representing a spectrum of key stakeholders in melanoma including academic investigators, pharmaceutical and biotech company representatives, melanoma advocates from various different non-profit organizations, donors and government officials.